PREVAIL THERAPEUTICS
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
PREVAIL THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2017-01-01
Status:
Active
Contact:
917-336-9310
Email Addresses:
[email protected]
Total Funding:
129 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network Font Awesome
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Aopia Biosciences
Aopia Biosciences is a biotechnology business focused on developing cutting-edge bioengineering solutions and technologies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
E-Health Now LLC
We are the first HIPAA compliant platform that focuses on optimizing cancer treatment plans for patients in China locally, on a B2B model.
GPS Dental
GPS Dental is a Dental Service Organization that provides care to communities through philanthropic service.
Modis Therapeutics
Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
EcoR1 Capital
EcoR1 Capital investment in Series B - Prevail Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Prevail Therapeutics
Adage Capital Management
Adage Capital Management investment in Series B - Prevail Therapeutics
OrbiMed
OrbiMed investment in Series B - Prevail Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Prevail Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Series B - Prevail Therapeutics
Pontifax
Pontifax investment in Series B - Prevail Therapeutics
Omega Funds
Omega Funds investment in Series B - Prevail Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Prevail Therapeutics
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series B - Prevail Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-05-17 | Scribe Therapeutics | Prevail Therapeutics investment in Convertible Note - Scribe Therapeutics | N/A |
More informations about "Prevail Therapeutics"
About Us - Prevail Therapeutics
Prevail was founded in a collaborative effort by Asa Abeliovich, M.D., Ph.D., OrbiMed and The Silverstein Foundation for Parkinson’s with GBA, who shared a common vision: to eradicate Parkinson’s disease and related disorders. We …See details»
Patients and Families - Prevail
Enrolling in Prevail’s clinical trials is the primary way that patients and caregivers who seek access to Prevail’s investigational drug(s) may receive those drug(s). Information about Prevail’s ongoing clinical trials can be found on …See details»
Lilly Completes Acquisition of Prevail Therapeutics
INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: …See details»
Lilly Completes Acquisition of Prevail Therapeutics
Jan 22, 2021 This press release contains forward-looking statements about Lilly'sacquisition of Prevail Therapeutics Inc. ("Prevail"), regarding contingent consideration amounts and terms, …See details»
Prevail Therapeutics - Crunchbase Investor Profile
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for …See details»
Lilly Announces Agreement to Acquire Prevail Therapeutics
Dec 15, 2020 INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a …See details»
Lilly acquires biotechnology company Prevail Therapeutics for …
Mar 24, 2022 Lilly concluded the acquisition through the merger of Tyto Acquisition with and into Prevail, with Prevail becoming Lilly’s wholly owned subsidiary. Cell & Gene Therapy Coverage …See details»
Lilly Announces Agreement to Acquire Prevail Therapeutics - PR …
Dec 15, 2020 About Prevail Therapeutics Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease …See details»
Lilly Completes Acquisition of Prevail Therapeutics - PR Newswire
Jan 22, 2021 This press release contains forward-looking statements about Lilly's acquisition of Prevail Therapeutics Inc. ("Prevail"), regarding contingent consideration amounts and terms, …See details»
Sangamo Therapeutics Announces Research Evaluation and …
BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 17, 2023-- Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation …See details»
Lilly Announces Agreement to Acquire Prevail Therapeutics
Dec 15, 2020 INDIANAPOLIS and NEW YORK, Dec. 15, 2020/ PRNewswire/-- Eli Lilly and Company and Prevail Therapeutics Inc. today announced a definitive agreement for Lilly to …See details»
Lilly Announces Agreement to Acquire Prevail Therapeutics
Dec 15, 2020 Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share …See details»
Lilly makes another gene therapy play with $1B deal to buy Prevail ...
Dec 15, 2020 Eli Lilly has joined the ranks of big pharma companies building a position in gene therapy, paying $26.50 per share to take control of New York-based Prevail Therapeutics and …See details»
Our Science - Prevail
Gaucher Disease. Gaucher disease is a rare genetic disorder driven by mutations in the GBA1 gene, that like PD-GBA, can cause lysosomal dysfunction and have a wide range of effects on …See details»
Lilly pays $880M for Prevail, pushing further into genetic medicine
Dec 15, 2020 Eli Lilly has agreed to buy gene therapy developer Prevail Therapeutics, announcing Tuesday a deal that could be worth more than $1 billion. Lilly will pay $880 million …See details»
A Conversation with Olga Uspenskaya, MD, PhD, of Prevail …
Jul 18, 2024 Recently, Prevail Therapeutics presented interim results from their Phase 1/2 open-label clinical trial assessing the safety and efficacy of their gene therapy to raise progranulin …See details»
Our Progress - News - Prevail
Prevail Therapeutics features on Behind the Mystery, a recurring series on The Balancing Act devoted to advocating for rare and genetic diseases. The episode, “Behind the Mystery of …See details»
Prevail Therapeutics - Overview, News & Similar companies
Apr 23, 2024 Who is Prevail Therapeutics. To prove more powerful than opposing forces. To be victorious. To gain ascendance through strength. To triumph. We are developing disease …See details»
Press Releases Archives - Prevail
INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement …See details»